1. Esensten, Jonathan H, Helou, Ynes A, Chopra, Gaurav, Weiss, Arthur, Bluestone, Jeffrey A. . CD28 Costimulation: From Mechanism to Therapy. In Immunity, 44, 973-88. doi:10.1016/j.immuni.2016.04.020. https://pubmed.ncbi.nlm.nih.gov/27192564/
2. Cappell, Kathryn M, Kochenderfer, James N. 2021. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. In Nature reviews. Clinical oncology, 18, 715-727. doi:10.1038/s41571-021-00530-z. https://pubmed.ncbi.nlm.nih.gov/34230645/
3. Xia, Sijing, Chen, Qin, Niu, Bing. . CD28: A New Drug Target for Immune Disease. In Current drug targets, 21, 589-598. doi:10.2174/1389450120666191114102830. https://pubmed.ncbi.nlm.nih.gov/31729942/
4. Nagai, Shigenori, Azuma, Miyuki. . The CD28-B7 Family of Co-signaling Molecules. In Advances in experimental medicine and biology, 1189, 25-51. doi:10.1007/978-981-32-9717-3_2. https://pubmed.ncbi.nlm.nih.gov/31758530/
5. Beyersdorf, N, Kerkau, T. . [CD28 costimulation and checkpoint inhibition in T cells]. In Der Internist, 61, 652-659. doi:10.1007/s00108-020-00813-0. https://pubmed.ncbi.nlm.nih.gov/32462247/